Navigation Links
DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year

New York, NY (PRWEB) January 24, 2013

The prescription drug resource center is alerting women who have used the vaginal ring contraceptive NuvaRing of new information added to the site showing trials are scheduled to begin this year for those claiming they suffered blood clots from the devices.

The mission of DrugRisk is to improve patient safety through education, including the latest drug warnings, recalls, studies and litigation news. “Many patients follow legal news for a drug they’re using to learn if others may be affected with similar problems and whether they have options,” explains DrugRisk representative Ryan Mayer.

DrugRisk contains warnings from experts linking vaginal rings like NuvaRing to higher blood clot risks than traditional birth control pills.

The British Medical Journal published a Danish study on May 10, 2012 linking vaginal rings like NuvaRing to as much as a 90% increased risk of blood clots over oral contraceptives.* On June 14, 2012, the New England Journal of Medicine also published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.** Nevertheless, there has still been no NuvaRing recall.

DrugRisk has also learned that, due to the number of patients filing a NuvaRing lawsuit, cases have been consolidated to a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.

Now, new information on the site shows that Judge Rodney Sippel, who is presiding over the federal court, has scheduled trials to begin on July 8, 2013.*** The latest U.S. Judicial Panel on MultiDistrict Litigation update showed NuvaRing lawsuits have risen by nearly 5% to 1076.****

This month, DrugRisk learned of research at Brigham and Women’s Faulkner Hospital which found that, while combined hormone vaginal ring contraceptives like NuvaRing can increase blood clot risks for all women, the risks are significantly higher for those suffering migraines.*****

Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of federal MDL drug injury cases, the DrugRisk Center only recommends lawyers and law firms who have already handled NuvaRing lawsuits.

For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit

***Order # 1423, Novenber 20, 2012, Case: 4:08-md-01964-RWS

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces New Pradaxa Health Warning From Australia
2. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
5. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
6. Cell Phone Radiation Lawsuit Update: ICEMS Position Paper Supports Italian Supreme Court Ruling on Cell Phones and Brain Tumors, Bernstein Liebhard LLP Reports
7. Transvaginal Mesh Lawsuit Update: New Study Concerning Use of Vaginal Mesh in Prolapse Procedures, Bernstein Liebhard LLP Reports
8. HRT Update: Therapy May Reduce Fractures, Boost Some Risks
9. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
10. Skechers Lawsuit on Behalf an Ohio Woman Who Sustained Serious Ankle Injury Allegedly Due to Shape-Ups' Defective Design Filed by Wright & Schulte LLC
11. New Class Action Lawsuit on Toddler’s Severe Burns from Glass-Fronted Fireplace: Now, AttorneyOne Can Provide Advice
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: